Marina Biotech - Hier 2012 Kursexplosion???

Seite 1 von 2
neuester Beitrag: 29.11.12 16:05
eröffnet am: 10.12.11 05:14 von: Vollzeittrade. Anzahl Beiträge: 37
neuester Beitrag: 29.11.12 16:05 von: speag Leser gesamt: 5523
davon Heute: 3
bewertet mit 3 Sternen

Seite: Zurück 1 | 2 Weiter  

2708 Postings, 4086 Tage VollzeittraderMarina Biotech - Hier 2012 Kursexplosion???

 
  
    
3
10.12.11 05:14

Eure Meinungen bitte zu dieser Perle:

Könnte es hier 2012 eine Kursexplosion geben? Zeichen stehen der Nachrichtenlage nach zu urteilen ziemlich gut!

Die letzten News lassen mehr erhoffen!

 
Seite: Zurück 1 | 2 Weiter  
11 Postings ausgeblendet.

2708 Postings, 4086 Tage VollzeittraderMarina go marina!!

 
  
    
10.01.12 20:18

2708 Postings, 4086 Tage VollzeittraderSchluss

 
  
    
10.01.12 20:32

auf th? Wäre super, lange nicht so positiv verlaufen! Jetzt die wende?

 

2708 Postings, 4086 Tage VollzeittraderHeut nachmittag

 
  
    
11.01.12 09:07

nochmal 18%??? Ich bitte drum ;)

 

2708 Postings, 4086 Tage VollzeittraderDer wind

 
  
    
11.01.12 09:12

2708 Postings, 4086 Tage VollzeittraderStimmung bei

 
  
    
11.01.12 09:26

den amis ist auf jeden fall postiver als die letzten tage ;)!

Mal schauen, wie es heut nachmittag abgeht ;)

 

2708 Postings, 4086 Tage VollzeittraderHeut ein grüner

 
  
    
19.01.12 16:36

2708 Postings, 4086 Tage VollzeittraderOhne news

 
  
    
19.01.12 16:45

so ein kurssprung... ob das so gesund ist :D

 

2708 Postings, 4086 Tage VollzeittraderInvestor gefunden??

 
  
    
19.01.12 16:47

Marinas rettung?? Was ist hier los??

 

2708 Postings, 4086 Tage VollzeittraderHeiliger strohsack :D

 
  
    
19.01.12 16:49

1,00 $, wir kommen!! =)

 

2708 Postings, 4086 Tage VollzeittraderRakete!!

 
  
    
19.01.12 16:51

Aber so ein anstieg kann nicht gesund sein :D

http://www.nasdaq.com/symbol/mrnad/real-time

 

2708 Postings, 4086 Tage VollzeittraderBei 0,96 USD

 
  
    
19.01.12 16:55

vorerst abgeprallt! Hat jemand news oder so??

 

2708 Postings, 4086 Tage VollzeittraderShort sqeeze??

 
  
    
19.01.12 17:28

2708 Postings, 4086 Tage VollzeittraderSchluss auf th

 
  
    
19.01.12 18:42

wäre top! Dann morgen hoffentlich den 1$!! Wäre ne super woche für marina!

 

2708 Postings, 4086 Tage VollzeittraderMal gucken,

 
  
    
20.01.12 13:08

vllt sehen wir heut ja endlich mal den 1,00 $! Bin gespannt!

 

2708 Postings, 4086 Tage VollzeittraderYeah, marina geht wieder ab =)

 
  
    
23.01.12 15:58

2708 Postings, 4086 Tage VollzeittraderZieh marina zieh ;)

 
  
    
30.01.12 15:54

80 Postings, 6952 Tage marathoniHammer News

 
  
    
14.03.12 23:59

BOTHELL, WA and ANN ARBOR, MI -- (Marketwire) -- 03/14/12 -- Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based drug discovery and development company, and ProNAi Therapeutics, Inc. (ProNAi), a privately-held biotechnology company pioneering DNA interference (DNAi) therapies for cancer, announced today that the Companies have entered into an Exclusive License Agreement regarding the development and commercialization of DNAi-based therapeutics utilizing Marina Biotech's novel SMARTICLES® liposomal delivery technology. ProNAi will have full responsibility for the development and commercialization of any products arising under the Agreement. Under terms of the Agreement, Marina Biotech could receive up to $14 million for each gene target in total upfront, clinical and commercialization milestone payments, as well as royalties on sales, with ProNAi having the option to select any number of additional gene targets. For example, if ProNAi licenses five products over time under this Agreement, Marina Biotech could receive up to $70 million in total milestones, plus royalties. Further terms of the Agreement were not disclosed.  "We are pleased that twenty-two patients have been dosed with PNT2258 in our Phase I clinical trial in advanced solid tumor patients to evaluate safety and tolerability, maximum tolerated dose, pharmacokinetics and pharmacodynamics. PNT2258 is our first DNAi oligonucleotide targeted against the anti-apoptotic bcl-2 oncogene and encapsulated in Marina's SMARTICLES® technology. This novel delivery technology offers protection for the DNAi oligonucleotide during systemic administration with good circulation times and extrahepatic tumor exposure. DNAi are short single-strand unmodified oligonucleotides designed to silence genes by interfering with DNA. The DNAi silencing approach is differentiated from that of RNAi, antisense or miRNA in that it targets genomic sequences within the noncoding region of DNA disrupting transcription. The progress and delivery validation in the clinic this past year on the novel DNAi-SMARTICLES® formulation gives us confidence to bring forward more first-in-class drug candidates alone or with partners. ProNAi is now positioned to advance additional cancer therapies from its pre-clinical leads targeting other oncogenes such as c-myc and k-ras while also exploring other disease targets in areas such as inflammation and genetics diseases," said Charles L. Bisgaier, Ph.D., President and CEO of ProNAi Therapeutics.  "We are extremely pleased to have entered into a relationship with a company like ProNAi that is developing a first-in-class nucleic acid therapeutic," stated J. Michael French, President and CEO of Marina Biotech. "In addition, we are excited to see the continued advancement of oligonucleotide-based therapeutics using our SMARTICLES® technology. Besides advancements within our own internal research programs, we have now been able to establish two license agreements broadening the application of the SMARTICLES® technology to the systemic administration of both single- and double-stranded oligonucleotide therapeutics. We look forward to the rapid advancement of ProNAi Therapeutics' clinical pipeline and the opportunity to bring novel therapeutics to patients in need."  ProNAi is conducting an open-label, single arm, Phase I dose-escalation study of PNT2258 in patients with advanced solid tumors for which no standard therapy exists at START in San Antonio, Texas. PNT2258 is ProNAi's first drug candidate from the DNAi drug platform. Patients receive PNT2258 as an intravenous infusion once daily for 5 consecutive days (Days 1-5) of every 21-day cycle (3 weeks). ProNAi plans to report the results of this Phase I study at oncology conferences later this year and initiate the next Phase I/II safety and efficacy studies in select cancer patients based upon the safety and dose findings from this Phase I study.

 

50 Postings, 4479 Tage speaggibts news?

 
  
    
26.11.12 20:01

50 Postings, 4479 Tage speaghomepage

 
  
    
28.11.12 13:28
www.marinabio.com

investor link funktioniert nicht mehr....  

50 Postings, 4479 Tage speagTekmira Pharmaceutical Obtains Licence For RNA Tec

 
  
    
29.11.12 15:24
Tekmira Pharmaceutical Obtains Licence For RNA Technology From Marina Biotech

http://www.nasdaq.com/article/...y-from-marina-biotech-20121129-00348  

50 Postings, 4479 Tage speagLöschung

 
  
    
29.11.12 16:04

Moderation
Zeitpunkt: 30.11.12 08:39
Aktion: Löschung des Beitrages
Kommentar: Löschung auf Wunsch des Verfassers

 

 

50 Postings, 4479 Tage speagRT Chart

 
  
    
29.11.12 16:05

http://ih.advfn.com/p.php?pid=staticchart&s=NO^MRNA&p=0&t=16&vol=1

 

Seite: Zurück 1 | 2 Weiter  
   Antwort einfügen - nach oben